Treatment of murine colitis by Lactococcus lactis secreting interleukin-10 |
| |
| Authors: | Steidler L Hans W Schotte L Neirynck S Obermeier F Falk W Fiers W Remaut E |
| |
| Institution: | Department of Molecular Biology, Ghent University and Flanders Interuniversity Institute for Biotechnology, K. L. Ledeganckstraat 35, 9000 Gent, Belgium. lothar.steidler@dmb.rug.ac.be |
| |
| Abstract: | The cytokine interleukin-10 (IL-10) has shown promise in clinical trials for treatment of inflammatory bowel disease (IBD). Using two mouse models, we show that the therapeutic dose of IL-10 can be reduced by localized delivery of a bacterium genetically engineered to secrete the cytokine. Intragastric administration of IL-10-secreting Lactococcus lactis caused a 50% reduction in colitis in mice treated with dextran sulfate sodium and prevented the onset of colitis in IL-10(-/-) mice. This approach may lead to better methods for cost-effective and long-term management of IBD in humans. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
